drugset / Trial / NCT03720353

Pharmacological Intervention for Symptomatic Snoring

NCT03720353 ↗

Phase 1/2 Completed 27 enrolled Brigham and Women's Hospital
RandomizedCrossoverQuadruple-blindTreatment

Summary

Currently, there is no pharmacological intervention capable of maintaining airway patency for the treatment of snoring and airflow limitation during sleep. Here we study the effect of pharmacological stimulation of the pharyngeal muscles on snoring severity, in a randomized quadruple-blind, crossover study.

Timeline

Start
2018-12-17
Primary completion
2019-12-10
Completion
2019-12-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Atomoxetine Other / unclassified 40 mg —
Comparator Atomoxetine Other / unclassified 80 mg —
Comparator Oxybutynin Small molecule 2.5 mg —
Comparator Oxybutynin Small molecule 5 mg —

Indications

No indication recorded.